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S100 proteinRAGE (receptor for advanced glycation end-products) is a multiligand receptor of the immunoglobulin super-
family involved in inﬂammation, diabetes, atherosclerosis, nephropathy, neurodegeneration, and cancer. Ad-
vanced glycation end-products, high mobility group box-1 (amphoterin), β-amyloid ﬁbrils, certain S100
proteins, and DNA and RNA are RAGE ligands. Upon RAGE ligation, adaptor proteins (i.e., diaphanous-1, TIRAP,
MyD88 and/or other as yet unidentiﬁed adaptors) associate with RAGE cytoplasmic domain resulting in signal-
ing. However, RAGE activation may not be restricted to pathological statuses, the receptor being involved in tis-
sue homeostasis and regeneration/repair upon acute injury, and in resolution of inﬂammation. RAGE effects are
strongly dependent on the cell type and the context, whichmay condition therapeutic strategies aimed at reduc-
ing RAGE signaling.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
RAGE (receptor for advanced glycation end-products) is a multiligand
receptor of the immunoglobulin superfamily long implicated in inﬂam-
mation, diabetes and its complications, atherosclerosis, nephropathy,
neurodegeneration, and cancer [1–9]. RAGE is a ~47–55 kDa protein
consisting of an extracellular regionmadeof V-, C1- andC2-type domains,
a short membrane-spanning domain, and a relatively short cytoplasmic
and transducingdomaindevoid of kinase activity. Thus, RAGEneeds to as-
sociate with adaptor proteins for intracellular signaling.
RAGE engagement results in the activation of multiple downstream
signaling pathways eventually impinging on canonical NF-κB, AP-1,
CREB, STAT3 [1–9], NFAT [10], andmyogenin [11] with consequent regu-
lation of transcription of cytokines, inﬂammatory enzymes, chemokines,
chemokine receptors, adhesion molecules, matrix metalloproteinases
and/or cytoskeletal constituents, and of cell proliferation, survival, differ-
entiation andmigration, phagocytosis and authophagy (Fig. 1). However,
the signaling pathways activated and functional consequences of RAGE
engagement are strongly dependent on the cell type, the context and
the identity and local concentration of its ligands, and impact the organi-
zation of the cytoskeleton besides transcription.
RAGE is expressed in a variety of cell types during prenatal and post-
natal development and repressed at completion of development ex-
cepting type I alveolar cells in the lung and a few other cell typestal Medicine and Biochemical
2 Perugia, Italy. Tel.: +39 075
rights reserved.[1,2]. This suggests that RAGE signalingmay play an important role dur-
ing development, although deletion of Rage does not result in fertility
disturbances or overt phenotypes excepting hyperactivity and in-
creased sensitivity to auditory stimuli in mice [12]. However, RAGE is
sharply upregulated in a large number of cell types under pathological
conditions, and RAGE ligands upregulate its expression [1–11] (Fig. 1).
These observations probably represent one main reason why RAGE ex-
pression and signaling mostly have been investigated in the context of
the pathophysiology of chronic inﬂammatory statuses and cancer.
However, recent evidence suggests that RAGE signalingmayplay an im-
portant role in the resolution of inﬂammation and in tissue homeostasis
and repair/regeneration after acute injury, highlighting the pleiotropic
activities of this receptor.
2. RAGE is a pattern recognition receptor
The multiligand nature of RAGE is highlighted by its ability to bind
such diverse ligands as advanced glycation end-products (AGEs) [13–
15], high mobility group box-1 (HMGB1, amphoterin) [13,14,16], β-
amyloid ﬁbrils [17], certain S100 proteins [3,18,19], and DNA and RNA
[6] (Fig. 1). AGEs form from condensation and oxidation processes be-
tween proteins or peptides and sugars, an event occurring in diabetes
and recognized as a major cause of diabetic complications such as accel-
erated atherosclerosis and cardiovascular disorders [5], nephropathy
[7,20,21], and chronic inﬂammation [4,6,22], in part via RAGE binding.
HMGB1 is conﬁned to the nucleus in normal physiological conditions,
functioning as a regulator of chromatin dynamics [23]; however, in
case of tissue injury itmoves to the cytoplasmand then is released, acting
as a danger signal [24,25]. HMGB1–RAGE interactions also participate in
tumorigenesis [4,6]. β-Amyloid results from proteolytic cleavage of the
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tion of which in the brain is a hallmark of Alzheimer's disease [26].
S100 proteins are Ca2+-binding proteins acting as intracellular regula-
tors and extracellular signals [27–29].
RAGE is found in an oligomeric or a pre-assembled state [30]; ligand
binding stabilizes RAGE oligomers, an event required for RAGE signaling.
TheV andC1domains forma single functional unit in theRAGEmolecule
and theVC1unit is linked to theC2 domain by aﬂexible linker. Structural
analyses have shown that with the exception of S100A6 which interacts
with RAGE C2 domain [31], all other RAGE ligands interact with the VC1
domain [32]. This would predict that AGEs, HMGB1, β-amyloid and the
majority of RAGE-activating S100 proteins should elicit similar if not
identical effects in the same cell type upon RAGE ligation. However,
structural properties intrinsic to individual ligands (e.g., their tendency
to form oligomers of variable complexity and sensitivity to the non-
reducing conditions of the extracellular milieu), the ligand concentra-
tion, the context, the cell type and the number of RAGE molecules
expressed on the cell surface may condition RAGE signaling.
RAGE VC1 domain has a net positive charge whereas the C2 domain
has a net negative one [33–35]. It has been proposed that the negatively
charged HMGB1 C-domain (which harbors the RAGE-binding site
[24,25]), AGEs and the acidic S100proteins are attracted by the positive-
ly charged area of RAGE's VC1 domain, implying that HMGB1–, AGE–
and S100 protein–RAGE interactions are electrostatic in nature
[33–35]. Thus, AGEs, HMGB1, S100 proteins and DNA and RNA should
compete with each other for RAGE binding; however, information
about this issue is surprisingly scant. RAGE in phagocytes also interactsA , AGEs, 
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Fig. 1. RAGE engagement by multiple ligands activates various signaling pathways in a cell-
oligomers) and association of the RAGE cytoplasmic domain with the adaptors Dia-1, TIRAP
ecules impinging on transcription factors NF-κB, AP-1,CREB, STAT3, and/or myogenin. In so d
ferentiation andmotility in a cell-speciﬁc manner. RAGE signaling-dependent regulation of c
Ras/PI3K/RhoA/ROCK and a Dia-1/Rac1/Cdc42/RhoA/ROCK pathway.with phosphatidylserine (an “eat-me” signal) [36] on the surface of
apoptotic cells thereby promoting efferocytosis, i.e. the phagocytosis of
apoptotic cells [37,38]. While these observations point to a beneﬁcial
role of RAGE in the clearance of apoptotic cells in tissue development,
homeostasis and repair and in resolution of inﬂammation, one would
predict that phosphatidylserine binds to the VC1 domain positively
charged area and that the reported HMGB1-dependent inhibition of
phagocytosis [39,40] may be due to the blockade of phosphatidylserine
by HMGB1, competition between HMGB1 and phosphatidylserine for
RAGE binding and/or to blockade of access of phosphatidylserine to
HMGB1-bound RAGE.
Conﬂicting conclusions have been drawn concerning the mode
S100B and perhaps other S100 proteins interact with RAGE. According
to one view these proteins bind to the positively charged area of the
VC1 domain [34], whereas according to another view they bind to the
C'D loop and at least part of a nearby hydrophobic surface located in an-
other region of the V domain [35].
RAGE also interacts through its V domain with heparan sulfate with
high afﬁnity, an interaction reported to be essential for HMGB1-
stimulated RAGE signaling in endothelial cells [41]. These studies have
established that RAGE binds heparan sulfate irrespective of the absence
or presence of HMGB1, suggesting that RAGE forms a complex with
heparan sulfate on the cell surface, i.e. heparan sulfate may act as a
RAGE coreceptor amplifying ligand-induced RAGE signaling. RAGE
alsomight bind to extracellular matrix heparan sulfate, and potentially,
HMGB1 (and other RAGE ligands as well) might regulate the extent of
RAGE interactions with extracellular matrix heparan sulfate. ThisAPP 
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speciﬁc manner. Ligand binding causes RAGE oligomerization (or stabilization of RAGE
-MyD88 and/or as yet unidentiﬁed adaptors (X), which in turn activate signaling mol-
oing, RAGE regulates the inﬂammatory response and/or cell proliferation, survival, dif-
ell motility also occurs independently of its effects on gene transcription via a Dia-1/Src/
103G. Sorci et al. / Biochimica et Biophysica Acta 1833 (2013) 101–109might have important implications for RAGE functions in physiology
and pathology.
3. RAGE signaling requires adaptor proteins
One adaptor protein involved in RAGE signaling transduction is
diaphanous-1 [42], a member of the formin family thatmediates the ef-
fects of the small GTPase of the Rho family, RhoA, on cell motility and
the cytoskeleton [43–45] and of Cdc42 and Rac1 signaling [46].
Diaphanous-1 recruits Rac1 and Cdc42 in glioma cells thereby driving
RAGE-dependent cell migration [42] (Fig. 1). Also, following RAGE liga-
tion by S100B in microglia, diaphanous-1 recruits Rac1/Cdc42 with en-
suing activation of a RhoA/ROCK and a Src kinase/Ras/PI3K/RhoA/ROCK
pathway governing microglial motility and a JNK/AP-1 pathway re-
sponsible for chemokine expression [47]. However, diaphanous-1 is
not required for S100B/RAGE-dependent activation of a Ras/MEK/
ERK1/2/NF-κB pathway concurring to chemokine expression inmicrog-
lia [48] (Fig. 1). Thus, additional adaptors may be recruited by activated
RAGE inmicroglia. Also, diaphanous-1may not mediate RAGE signaling
to Rac1/Cdc42 in myoblasts because HMGB1-dependent stimulation of
RAGE in these cells results in the acceleration of myogenic differentia-
tion and inhibition of proliferation via activation of a Rac1/Cdc42/
MKK6/p38 MAPK pathway and p38 MAPK-dependent inhibition of
ERK1/2 and JNK [48–50] whereas diaphanous-1 activity supports myo-
blast proliferation [51]. Other adaptor proteins involved in RAGE signal-
ing transduction are TIRAP and MyD88, two adaptor proteins for
Toll-like receptor (TLR)-2 and -4 [52] (Fig. 1). Speciﬁcally, upon binding
of ligands the cytoplasmic domain of RAGE is phosphorylated at Ser391
by protein kinase Cζ, which promotes TIRAP and MyD88 recruitment
and activation of inﬂammatory pathways. Incidentally, these results
point to cooperation between RAGE and TLRs in immune response.
Whether RAGE ligation recruits other adaptor proteins, possibly in a
cell-speciﬁc manner, remains to be determined.
4. RAGE ligation activates signaling pathways in a
cell-speciﬁc manner
Whereas RAGE-dependent stimulation of ERK1/2, Akt, p38MAPK and
JNK in monocytes/macrophages/microglia, astrocytes, endothelial cells,
chondrocytes and vascular smooth muscle cells causes cell activation
and/or proliferation during the course of inﬂammation, arthritis and/or
atherosclerosis [3,5], RAGE-dependent stimulation of ERK1/2 results in
enhanced survival of neuronal cells under oxidative stress
conditions [53–55] and enhanced proliferation of low-density myoblasts
[56], whereas HMGB1/RAGE-dependent stimulation of p38 MAPK in
myoblasts results in myogenic differentiation and reduced proliferation
andmigration [48,49] (Fig. 1).Moreover, excess RAGE stimulation in neu-
rons causes excessive ERK1/2 activation resulting in neurotoxic oxidative
stress leading to apoptosis [53]. Also, as mentioned above RAGE signaling
inmicroglia stimulatesmigration via a diaphanous-1/Src/Ras/PI3K/RhoA/
ROCK, an X/Ras/PI3K/RhoA/ROCK (where X is an unidentiﬁed adaptor
protein) and diaphanous-1/Rac1/RhoA/ROCK pathway [47], and in sever-
al cancer cells it stimulates invasiveness via activation of ERK1/2, p38
MAPK, JNK, Akt, Rac1, NF-κB and caspase-1 and production of matrix
metalloproteinase 9 [14,57–60] (Fig. 1). However, RAGE engagement by
HMGB1 inmyoblasts and in rhabdomyosarcoma cells induced to express
the receptor, reduces migration, invasiveness and release of matrix
metalloproteinases 1 and 2 via p38 MAPK activation [48–50]. Aside
from the nature of the adaptor protein recruited by RAGE in different
cell types, which may differentially condition the intensity and duration
of the activity of downstream signaling molecules, the overall effect of
RAGE ligation may be strongly dependent on intervening intracellular
events such as the amount of produced reactive oxygen species (ROS),
the redox status, energy metabolism and cell-speciﬁc transcription and
activity of deﬁnite genes.5. S100 proteins and β-amyloid form oligomers
In the extracellular space S100proteins assemble intomultimeric (tet-
rameric, hexameric, octameric and/or higher-order) complexes [61–66],
which stabilize RAGE oligomers thus promoting the close association of
intracellular domains of RAGE molecules required for the recruitment of
adaptor proteins and/or enzymes [30,32]. Possibly, the larger the amount
of S100oligomers the greater the stabilization of RAGE aggregates and the
more intense and/or sustained the RAGE signaling. This mechanismmay
explain the different outcomes of, e.g. S100B-stimulated RAGE signaling
inneurons andmicroglia: S100Bat lowdosespromotesneuronal survival,
stimulates neurite outgrowth and counteracts microglia activation
[53,54,67],whereas at high doses it kills neurons [53,54] and activatesmi-
croglia [68,69] and astrocytes [70]. As another mechanism, the extent of
ligand-induced RAGE oligomerization/stabilization, which may be larger
at high S100B concentrations (i.e., in the presence of high amounts of
high-order S100B oligomers) and/or in the presence of β-amyloid ﬁbrils,
and the cell type identity may dictate the nature of the adaptor protein
recruited. For example, the different ability of neurons and of microglia
and astrocytes to manage oxidative stress may explain the different out-
comes of highly intense RAGE signaling in these cell types. Moreover, as
RAGE ligands upregulate RAGE expression [2], the greater number of
expressed RAGE molecules at high ligand concentrations may translate
into a more sustained RAGE signaling via the recruitment of different
adaptor proteins. Lastly, different ratios of levels of RAGE and advanced
glycation end products receptor 1, which counteracts RAGE [71], may
be responsible for the different outcomes of RAGE ligation of high
S100B in neurons and microglia.
Among the S100 proteins that are RAGE ligands, S100B is the only one
exerting different RAGE-mediated effects at low and high concentrations
on the same cell type [29]. S100A4, S100A8/S100A9 and S100A12 also
exert extracellular effects in part via RAGE engagement [29,72–75]. How-
ever, relatively high concentrations of these proteins are required for
RAGE activation, and they mostly are involved in chronic inﬂammation
and cancer. There are exceptions to this rule, however. One exception is
represented by S100A12, shown to exert a potent neurite extension ac-
tivity at concentrations between 0.1 and 1.0 μM and decreasing activity
at higher concentrations [76]. However, RAGE engagement in this case
was supposed, but not ﬁrmly demonstrated. Analogously, S100A4 at
high but not low concentrations promotes neurite extension, yetwithout
activating RAGE, the protein binding to heparan sulfate that presumably
acts as a coreceptor of an unknown receptor [77]. Also, the S100A8/
S100A9 heterocomplex at low concentrations activates RAGE to promote
tumor cell growth [78] and may act as a potent pro-apoptotic agent, but
this latter activity occurs in a RAGE-independent manner [79]. The three
so-called calgranulins, S100A8, S100A9 and S100A12, may exert protec-
tive effects in relation to tissue repair and remodeling, acting as chemo-
kine mediators in response to infection and activating mast cells,
neutrophils, keratinocytes,macrophages and dendritic cells, upregulating
adhesion molecules required for extravazation, and inhibiting microbial
growth [reviewed in Refs. 29,73]. However, these proteins can also acti-
vate TLR-4 and G-protein-coupled receptors, and their antimicrobial ef-
fects are independent of RAGE.
β-Amyloid is known to form oligomers which intensely activate
RAGE in neurons and microglia with deleterious effects. Indeed, the
participation of RAGE signaling in neurodegenerative diseases via di-
rect effects on neurons and indirect effects through microglia and as-
trocyte activation is long recognized [17,80,81]. However, in vitro
data suggest that low S100B-activated RAGE counteracts the detri-
mental effects of β-amyloid on neuronal survival, whereas high
S100B-activated RAGE potentiates these effects [54].
6. RAGE ligands upregulate RAGE expression
Re-expression of RAGE after completion of developmentoccurs in in-
jured tissues under the action of a ROS/NF-κB axis [2], and engagement
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sides activating RAGE signaling, RAGE ligands upregulate RAGE expres-
sionmostly, but not exclusively via activation of NF-κB, which translates
into an increased density of RAGEmolecules at the cell surface and con-
sequent enhancement of the intensity and duration of RAGE signaling
[2] (Fig. 1). This feed-forward mechanism can be interrupted by de-
creasing the concentration of RAGE ligands, ROS production and/or
NF-κB signaling, whereas a reduced clearance of RAGE ligands and/or a
continuous release of RAGE ligands from the injured tissue may perpet-
uate RAGE signaling and amplify RAGE-dependent cell responses. In this
context, proteins acting as RAGE ligands are generally viewed as
damage-associated molecular patterns [82]. However, in normal physi-
ological conditions at least one RAGE ligand, i.e. S100B, is found in the
brain extracellular space at a concentration (a few nM or less) sufﬁcient
to activate RAGE [83]. Because RAGE is expressed in low, but appreciable
amounts in neurons and microglia in normal brain [84], S100B might
tonically activate a low-intensity RAGE signaling in neurons resulting
in trophic effects, and in microglia resulting in attenuation of microglial
reactivity [54,85]. However, in the context of gliomas interaction of low
S100Bwith RAGEmay induce tolerance ofmicroglia thus contributing to
local tumor immunosuppression [85]. Whether low S100B-activated
RAGE has a role in the beneﬁcial activity of microglia [86,87] and in neu-
ronal electric activity in normal physiological conditions remains to be
investigated. Moreover, whereas early after acute muscle injury a ROS/
NF-κB axis induces RAGE expression in activatedmuscle stem (satellite)
cells, in differentiatingmyoblasts RAGE expression is regulated positive-
ly and negatively by myogenin and PAX7, respectively [11]; S100B and
HMGB1 upregulate RAGE expression in low-density myoblasts [56],
whereas HMGB1 only does so in high-density myoblasts [11].
7. Cell type identity conditions effects of RAGE ligation
Interestingly, RAGE expressing cells are not homologous to each other
in terms of functional responses to RAGE ligation. On the one side, cells of
the innate and adaptive immune system, endothelial and vascular
smooth muscle cells and chondrocytes respond to RAGE activation by
amplifying their responses in the context of inﬂammatory processes, dia-
betic complications and atherosclerosis [3,5–8,88–91]. Thus, strategies
aimed at reducing RAGE signaling may contribute to reduce the inﬂam-
matory response especially in chronic inﬂammatory settings, with poten-
tial therapeutic beneﬁts [92,93]. On the other hand, at least neurons and
skeletalmuscle satellite cells appear to beneﬁt froma low-intensity RAGE
signaling in terms of resistance to apoptotic stimuli and activation of the
differentiation program (neurons) [13,53], and of activation of the differ-
entiation program and stimulation of apoptosis-mediated elimination of
superﬂuous cells (myoblasts) [11,48,49,56]. Also, whereas RAGE signal-
ing in carcinomas, mesotheliomas and gliomas sustains tumorigenesis
andmetastasis development [14,57–60], RAGE expression and/or activa-
tion in rhabdomyosarcoma cell lines results in reduced proliferation, mi-
gration, invasiveness and tumorigenesis [50], and RAGE expression and/
or activation is reduced in certain lung and oral and esophageal tumors
[94–96] and embryonal rhabdomyosarcoma [F. Riuzzi, G. Sorci,
R.Sagheddu and R. Donato,manuscript in preparation]. As another exam-
ple, whereas S100A4-dependent RAGE activation in chondrocytes results
in the erosion of articular cartilage via upregulation and activation ofma-
trix metalloproteinases [97], S100A4-dependent RAGE activation in
cardiomyocytes may be protective [98]. Thus, the outcome of RAGE sig-
naling is strongly cell type- and context-dependent, which may limit
therapeutic strategies aimed at reducing RAGE signaling. Probably, the
contradictory effects of RAGE signaling depend on the intensity and dura-
tion of RAGE signaling and on intrinsic properties RAGE-expressing cells.
8. RAGE promotes autophagy
RAGE ligation in several cell types promotes autophagy, a genetically
programmed, evolutionarily conserved cell survival process, and inhibitsapoptosis by a p53 transcription-independent pathway during the re-
sponse to chemotherapeutic agents [99,100]. This RAGE activity may
concur to tumorigenesis. Also, RAGEmediatesβ-amyloid-induced forma-
tion of autophagosomes in neuronal cells via CaMKKβ-AMPK signaling
[101] with potential detrimental effects in Alzheimer's disease conse-
quent to excess autophagy (Fig. 1). Yet, because authophagy is not detri-
mental per se [102–104], RAGE-dependent promotion of authophagy
may be beneﬁcial during the course of development and tissue regener-
ation, an as yet unexplored issue. On the other hand, RAGE signaling can
promote apoptosis via enhanced ROS production in neuronal cells
[17,53],myoblasts [48,49] and cardiomyocytes [105,106]. Thus, RAGE ap-
pears to play an important role in the delicate balance between cell sur-
vival (via stimulation of autophagy and inhibition of apoptosis) and cell
death (via stimulation of apoptosis and excess authophagy) depending
on the intensity and/or duration of its activity, which are largely depen-
dent on the local concentrations of its ligands and the context.
9. RAGE in resolution of inﬂammation
There is consensus that RAGE signaling is not causative of inﬂamma-
tion; rather, RAGE signaling in monocytes/macrophages/microglia per-
petuates inﬂammation by promoting phagocyte inﬁltration and the
release of proinﬂammatory cytokines and chemokines. Indeed, interfer-
ence with RAGE signaling in chronic inﬂammatory conditions results in
amelioration of clinical and biochemical signs of inﬂammation [92,93].
However, recent evidence suggests that RAGE may be important for
the attenuation and/or resolution of acute inﬂammation aswell. Indeed,
RAGE signaling limits the inﬂammatory and procoagulant response
during Escherichia coli sepsis [107] and is protective during murine
tuberculosis [108]. Also, S100B-activated RAGE signaling leads to reso-
lution of inﬂammation in Aspergillus fumigatus infection in lung. Specif-
ically, TLR-2 activation on bronchial epithelial cells by the fungus results
in the upregulation and release of S100B, that paracrinally binds to
RAGE on neutrophils and mediates its association with TLR-2 [109]
(Fig. 2). By this mechanism, S100B-activated RAGE inhibits TLR-2 in
neutrophils and restrains A. fumigatus-induced pulmonary inﬂamma-
tion [109]. However, when used at high doses S100B exacerbates A.
fumigatus-induced pulmonary inﬂammation [109] likely via sustained
stimulation of RAGE signaling. Also, in other lung pathological settings
such as pneumococcal and inﬂuenza virus A pneumonia RAGE signaling
is detrimental [110,111], which points to the different roles of RAGE in
pathogen-induced inﬂammation perhaps depending on the identity
and/or concentration of RAGE ligands, the intervening leukocyte popu-
lation and the amount of expressed RAGE. In this regard, it is interesting
that susceptibility to invasive aspergillosis in patients undergoing he-
matopoietic stem cell transplantation is signiﬁcantly associated with
RAGE (–374T/A) polymorphism resulting in RAGE overexpression in re-
cipients, and with S100B (+427C/T) polymorphism resulting in S100B
overexpression in donors [112]. Lastly, lack of RAGE results in lung ﬁ-
brotic disease [113,114] pointing to an important role of RAGE in pul-
monary tissue homeostasis. RAGE (AGER) is expressed in great
abundance in type I alveolar epithelial cells [1,2], with a potential role
in epithelium–extracellular matrix interactions given RAGE's ability to
bind to heparan sulfate with a high afﬁnity [41]. In humans, the RAGE
variant rs2070600 has been associated with potential disturbances of
RAGE structure and function in relation to host defense, inﬂammation,
and tissue remodeling [115,116].
10. RAGE in tissue repair
In addition to its detrimental role in chronic inﬂammatory status-
es, RAGE signaling counteracts the beneﬁcial effects of MyD88 activity
during liver regeneration [117]. However, an increasing body of evi-
dence indicates that RAGE signaling has a beneﬁcial role in tissue re-
pair after acute injury which also calls for caution in anti-RAGE-based
therapeutic procedures. For example, RAGE becomes expressed in
RAGE TLR2
S100B
Neutrophil
RAGE-dependent 
inhibition of TLR2
Release 
of S100B
Fungal 
infection
Epithelial cell
Reduced inflammatory 
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TLR2
Fig. 2. RAGE promotes resolution of inﬂammation. TLR2 activation on bronchial epithelial
cells by Aspergillus conidia results in the upregulation and release of S100B that paracrinally
binds to RAGE on neutrophils, and mediates its association with TLR2 for subsequent inhi-
bition.However, S100B, upon binding to nucleic acids in epithelial cells, also activates an in-
tracellular TLR3/TLR9/TRIF/NF-κB-dependent pathway culminating in the transcriptional
downregulation of S100B [109]. This latter mechanism provides the molecular basis for
an evolving braking circuit in infection whereby the endogenous danger protects the host
against pathogen-induced inﬂammation and a nucleic acid-sensing mechanism resolves
danger-induced chronic inﬂammation.
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nerve injury and reduction of RAGE activity in acutely injured periph-
eral nerves results in the suppression of anatomical regeneration and
functional recovery [118,119], supporting a role of RAGE in neurite
outgrowth in vivo (Fig. 3A). S100B and HMGB1 are RAGE ligands in
macrophages stimulating RAGE signaling ultimately resulting in
nerve repair. Also, S100B-activated RAGE promotes Schwann cell mi-
gration during the course of repair of injured peripheral nerves
through the induction of the expression of thioredoxin interacting
protein and the consequent activation of p38 MAPK, CREB and
NF-κB [120]. Thus, RAGE signaling may intervene in peripheral
nerve regeneration via stimulation of macrophage and Schwann cell
migration to the site of damage (Fig. 3A): macrophages inﬁltrating
the injured tissue exert beneﬁcial effects by clearing cell debris and
dead neutrophils and releasing trophic factors, whereas activated
Schwann cells release cytokines and neurotrophic factors shown to
be crucial for the repair of injured nerves. The ability of RAGE signal-
ing, activated by either HMGB1 or S100B, to promote neurogenesis in
the subventricular zone of the adult mouse brain [121] adds to the
notion that RAGE transduces neurotrophic effects playing an impor-
tant role in nervous system repair.
As another example, deletion of Rage results in delayed regeneration
of acutely injured skeletal muscles [11]. RAGE is not expressed in adult
skeletal muscle tissue in normal physiological conditions and becomes
expressed in muscle satellite cells early after acute injury in a ROS/
NF-κB-dependentmanner with further expression inmyocytes (i.e., dif-
ferentiatedmyoblasts) being sustained by themuscle-speciﬁc transcrip-
tion factor, myogenin [11]. RAGE activity in myoblasts is sequentially
stimulated by S100B and HMGB1 which are released from injured
myoﬁbers with distinct kinetics thus contributing to the expansion of
the myoblast population and myogenic differentiation, respectively
[11,56] (Fig. 3B). Besides, deletion of Rage results in delayed inﬁltration
of injuredmuscle tissuewithmacrophages [11] (Fig. 3B), known to con-
tribute tomuscle regeneration. Thus, the absence of RAGE is detrimental
twice to muscle regeneration due to delayed macrophage inﬁltration ofinjured tissue and delayed differentiation of activated satellite cells.
However, a delayed, strong macrophage inﬁltration occurs in Rage−/−
injured muscles likely in relation to delayed efferocytosis with potential
exacerbation of detrimental effects of inﬂammation [11]. Lastly, com-
paredwith control muscles uninjured Rage−/−muscles exhibit elevated
satellite cell numbers which further increase following injury as a result
of elevated asymmetric division [11], which points to an important role
of RAGE in muscle satellite cell homeostasis.
Interestingly, muscle satellite cells isolated from aged (>72-years
old) human subjects show defective differentiation into fusion-
competent myocytes and defective expression of RAGE, and transient
transfection with RAGE restores their differentiation potential in part
[122]. Also, at odds with the accepted tumorigenic role of RAGE sig-
naling in most tumors, embryonal rhabdomyosarcomas show absent
or reduced RAGE expression and no myogenic potential, and ectopic
RAGE expression in embryonal rhabdomyosarcoma cell lines results
in reduced tumor formation in vivo and a partial restoration of their
myogenic potential in vitro [50]. Thus, it is possible that absent or re-
duced RAGE signaling in activated muscle satellite cells may concur to
progression of embryonal rhabdomyosarcomas given that these latter
originate from activated, proliferating satellite cells [123] and
Rage−/−myoblasts exhibit a high proliferation rate, migration and in-
vasiveness, and defective myogenic potential [11].
Moreover, HMGB1-induced RAGE signaling in cardiac ﬁbroblasts
results in the release of a number of factors responsible for
cardiomyocyte migration and proliferation potentially leading to car-
diac muscle regeneration [124]. Lastly, a role for RAGE in keratinocyte
proliferation and migration and wound closure has been proposed
[125].11. Conclusions and unanswered questions
The pathogenic role of RAGE in chronic inﬂammation and epithelial
cancer is undisputed. However, increasing evidence suggests that RAGE
signaling is not restricted to these disease states. Also, the widespread
expression of RAGE during development, in contrast to the repression
of RAGE expression in the vast majority of cell types upon completion
of development, points to an important, albeit as yet undisclosed role
of this receptor during embryonic and early postnatal life. The fact that
Rage−/− mice develop normally and show no overt phenotype does
not exclude that RAGE signaling may play a regulatory role in develop-
ing tissues: absence of RAGE signaling in Rage−/− animal models might
well be compensated by the activity of other receptors belonging to the
same superfamily. Aside from the potential importance of RAGE during
development, evidence begins to be offered that RAGE signaling partic-
ipates in the resolution of inﬂammation and in tissue regeneration, es-
pecially in acutely injured tissues where re-expression of RAGE occurs.
Also, absent or reduced RAGE signaling in activated muscle satellite
cells may concur to rhabdomyosarcomagenesis, and absent or altered
RAGE signaling results in lung ﬁbrosis. Thus, RAGE is likely to represent
one main factor intervening in the ﬁne regulation of the balance be-
tween injury and repair: short-term (i.e., up to a few days) RAGE signal-
ing triggered by low concentrations of its ligands may support tissue
homeostasis and concur to tissue repair by promoting cell proliferation
and differentiation, whereas long-term (i.e., weeks to months) RAGE
signaling triggered by high concentrations of its ligands may be delete-
rious by amplifying andperpetuating the inﬂammatory response, exces-
sively stimulating cell survival, proliferation and migration or causing a
lethal accumulation of ROS. In this scenario, the ability of RAGE ligands
to upregulate RAGE expression appears to play a fundamental role in
the friend or foe behavior of this receptor in that the higher their local
concentration in case of tissue injury the greater the number of
expressed RAGE molecules and the probability of RAGE's foe behavior.
Cell type identity (i.e., cell intrinsic properties) and the local environ-
ment also appear to condition the outcome of RAGE signaling. The
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Fig. 3. RAGE promotes regeneration of acutely injured tissue. (A) Upon acute injury of peripheral nerves RAGE becomes expressed in activated Schwann cells and in inﬁltrating
mononuclear phagocytes [118–120]. S100B and HMGB1 attract macrophages and promote Schwann cell migration to the damage site RAGE-dependently and stimulate both, mac-
rophages and Schwann cells, which concur to nerve repair. (B) Upon acute skeletal muscle injury, RAGE engagement in activated satellite cells results in their proliferation and
differentiation ultimately leading to regeneration. Under the action of S100B, which is sharply and abundantly released from myoﬁbers on day 1 post-injury [56], RAGE signaling
in satellite cells promotes proliferation via ERK1/2 and simultaneously activates the myogenic program via p38 MAPK [56]. Once sufﬁcient amounts of the muscle-speciﬁc transcrip-
tion factor, myogenin, have accumulated under the action of p38 MAPK (activated by HMGB1, which is released in high abundance from injured myoﬁbers beginning at day 3
post-injury [56]), activated satellite cells stop proliferating and differentiate into fusion-competent myocytes that build up new myoﬁbers and/or repair damaged myoﬁbers
[11]. Released S100B also attracts macrophages to the damage site RAGE-dependently (unpublished results); inﬁltrating macrophages concur to muscle regeneration.
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RAGE signaling for therapeutic purposes.
From the side of RAGE biology future work should address the fol-
lowing questions:
1. Do RAGE ligands compete with each other for RAGE binding?
2. Are there adaptor proteins other than diaphanous-1, TIRAP and
MyD88 mediating RAGE signaling?
3. What is the role of RAGE in tissue development?
4. Does RAGE play a widespread role in tissue regeneration/repair?
5. Is RAGE expressed in embryonic and/or adult stem cells? Or is it
expressed in activated stem cells only, perhaps in a tissue-speciﬁc
manner?
6. Is RAGE-dependent promotion of authophagy beneﬁcial during de-
velopment and tissue regeneration?
7. Which transcription factors in addition to NF-κB, myogenin and
PAX7 regulate RAGE expression?
8. Is a low-intensity RAGE signaling beneﬁcial to cells?
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